1997年Ilkova等[1]率先对伴有严重高血糖的新诊断2型糖尿病患者进行短期胰岛素强化治疗并取得了显著的临床疗效,随后不断有来自中国和国外的临床研究证实了短期胰岛素强化治疗对新诊断2型糖尿病患者具有消除高血糖毒性,修复改善受损的β细胞功能的独特优势。2013年中华医学会糖尿病学分会推出了新诊断2型糖尿病患者短期胰岛素强化治疗专家共识[2],进一步推动了短期胰岛素强化治疗在临床中的规范 In 1997, Ilkova et al [1] pioneered the short-term intensive insulin therapy of newly diagnosed type 2 diabetic patients with severe hyperglycemia and achieved significant clinical effects. Subsequently, there are continuous clinical studies from China and abroad confirming the short-term insulin intensive treatment It has the unique advantage of eliminating hyperglycemic toxicity and repairing the damaged β-cell function in newly diagnosed type 2 diabetic patients. In 2013, the Diabetes Branch of the Chinese Medical Association launched a new consensus on short-term insulin-intensive therapy in patients with type 2 diabetes mellitus [2], further promoting the clinical practice of short-term insulin-intensive therapy